Efficacy of favipiravir in adults with mild COVID-19 : a randomized, double-blind, multicentre, placebo-controlled clinical trial
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved..
OBJECTIVE: To evaluate whether favipiravir reduces the time to viral clearance as documented by negative RT-PCR results for severe acute respiratory syndrome coronavirus 2 in mild cases of coronavirus disease 2019 (COVID-19) compared to placebo.
METHODS: In this randomized, double-blinded, multicentre, and placebo-controlled trial, adults with PCR-confirmed mild COVID-19 were recruited in an outpatient setting at seven medical facilities across Saudi Arabia. Participants were randomized in a 1:1 ratio to receive either favipiravir 1800 mg by mouth twice daily on day 1 followed by 800 mg twice daily (n = 112) or a matching placebo (n = 119) for a total of 5 to 7 days. The primary outcome was the effect of favipiravir on reducing the time to viral clearance (by PCR test) within 15 days of starting the treatment compared to the placebo group. The trial included the following secondary outcomes: symptom resolution, hospitalization, intensive care unit admissions, adverse events, and 28-day mortality.
RESULTS: Two hundred thirty-one patients were randomized and began the study (median age, 37 years; interquartile range (IQR): 32-44 years; 155 [67%] male), and 112 (48.5%) were assigned to the treatment group and 119 (51.5%) into the placebo group. The data and safety monitoring board recommended stopping enrolment because of futility at the interim analysis. The median time to viral clearance was 10 days (IQR: 6-12 days) in the favipiravir group and 8 days (IQR: 6-12 days) in the placebo group, with a hazard ratio of 0.87 for the favipiravir group (95% CI 0.571-1.326; p = 0.51). The median time to clinical recovery was 7 days (IQR: 4-11 days) in the favipiravir group and 7 days (IQR: 5-10 days) in the placebo group. There was no difference between the two groups in the secondary outcome of hospital admission. There were no drug-related severe adverse events.
CONCLUSION: In this clinical trial, favipiravir therapy in mild COVID-19 patients did not reduce the time to viral clearance within 15 days of starting the treatment.
| Errataetall: |
CommentIn: Clin Microbiol Infect. 2022 Oct;28(10):1399. - PMID 35562086 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases - 28(2022), 4 vom: 01. Apr., Seite 602-608 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bosaeed, Mohammad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amides |
|---|
| Anmerkungen: |
Date Completed 05.04.2022 Date Revised 07.12.2022 published: Print-Electronic CommentIn: Clin Microbiol Infect. 2022 Oct;28(10):1399. - PMID 35562086 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cmi.2021.12.026 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335612423 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335612423 | ||
| 003 | DE-627 | ||
| 005 | 20231225230239.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cmi.2021.12.026 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1118.xml |
| 035 | |a (DE-627)NLM335612423 | ||
| 035 | |a (NLM)35026375 | ||
| 035 | |a (PII)S1198-743X(21)00734-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bosaeed, Mohammad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy of favipiravir in adults with mild COVID-19 |b a randomized, double-blind, multicentre, placebo-controlled clinical trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.04.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Clin Microbiol Infect. 2022 Oct;28(10):1399. - PMID 35562086 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVE: To evaluate whether favipiravir reduces the time to viral clearance as documented by negative RT-PCR results for severe acute respiratory syndrome coronavirus 2 in mild cases of coronavirus disease 2019 (COVID-19) compared to placebo | ||
| 520 | |a METHODS: In this randomized, double-blinded, multicentre, and placebo-controlled trial, adults with PCR-confirmed mild COVID-19 were recruited in an outpatient setting at seven medical facilities across Saudi Arabia. Participants were randomized in a 1:1 ratio to receive either favipiravir 1800 mg by mouth twice daily on day 1 followed by 800 mg twice daily (n = 112) or a matching placebo (n = 119) for a total of 5 to 7 days. The primary outcome was the effect of favipiravir on reducing the time to viral clearance (by PCR test) within 15 days of starting the treatment compared to the placebo group. The trial included the following secondary outcomes: symptom resolution, hospitalization, intensive care unit admissions, adverse events, and 28-day mortality | ||
| 520 | |a RESULTS: Two hundred thirty-one patients were randomized and began the study (median age, 37 years; interquartile range (IQR): 32-44 years; 155 [67%] male), and 112 (48.5%) were assigned to the treatment group and 119 (51.5%) into the placebo group. The data and safety monitoring board recommended stopping enrolment because of futility at the interim analysis. The median time to viral clearance was 10 days (IQR: 6-12 days) in the favipiravir group and 8 days (IQR: 6-12 days) in the placebo group, with a hazard ratio of 0.87 for the favipiravir group (95% CI 0.571-1.326; p = 0.51). The median time to clinical recovery was 7 days (IQR: 4-11 days) in the favipiravir group and 7 days (IQR: 5-10 days) in the placebo group. There was no difference between the two groups in the secondary outcome of hospital admission. There were no drug-related severe adverse events | ||
| 520 | |a CONCLUSION: In this clinical trial, favipiravir therapy in mild COVID-19 patients did not reduce the time to viral clearance within 15 days of starting the treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Clinical trial | |
| 650 | 4 | |a Favipiravir | |
| 650 | 4 | |a Mild COVID-19 | |
| 650 | 4 | |a Non-severe SARS-CoV-2 | |
| 650 | 7 | |a Amides |2 NLM | |
| 650 | 7 | |a Pyrazines |2 NLM | |
| 650 | 7 | |a favipiravir |2 NLM | |
| 650 | 7 | |a EW5GL2X7E0 |2 NLM | |
| 700 | 1 | |a Alharbi, Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Mahmoud, Ebrahim |e verfasserin |4 aut | |
| 700 | 1 | |a Alrehily, Sanaa |e verfasserin |4 aut | |
| 700 | 1 | |a Bahlaq, Mohannad |e verfasserin |4 aut | |
| 700 | 1 | |a Gaifer, Zied |e verfasserin |4 aut | |
| 700 | 1 | |a Alturkistani, Hanan |e verfasserin |4 aut | |
| 700 | 1 | |a Alhagan, Khaled |e verfasserin |4 aut | |
| 700 | 1 | |a Alshahrani, Saad |e verfasserin |4 aut | |
| 700 | 1 | |a Tolbah, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Musattat, Abrar |e verfasserin |4 aut | |
| 700 | 1 | |a Alanazi, Maha |e verfasserin |4 aut | |
| 700 | 1 | |a Jaha, Raniah |e verfasserin |4 aut | |
| 700 | 1 | |a Sultana, Khizra |e verfasserin |4 aut | |
| 700 | 1 | |a Alqahtani, Hajar |e verfasserin |4 aut | |
| 700 | 1 | |a Al Aamer, Kholoud |e verfasserin |4 aut | |
| 700 | 1 | |a Jaser, Saud |e verfasserin |4 aut | |
| 700 | 1 | |a Alsaedy, Abdulrahman |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Ayoub |e verfasserin |4 aut | |
| 700 | 1 | |a Abalkhail, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a AlJohani, Sameera |e verfasserin |4 aut | |
| 700 | 1 | |a Al Jeraisy, Majed |e verfasserin |4 aut | |
| 700 | 1 | |a Almaziad, Sultan |e verfasserin |4 aut | |
| 700 | 1 | |a Albaalharith, Nahlah |e verfasserin |4 aut | |
| 700 | 1 | |a Alabdulkareem, Khaled |e verfasserin |4 aut | |
| 700 | 1 | |a Alshowair, Abdulmajeed |e verfasserin |4 aut | |
| 700 | 1 | |a Alharbi, Naif Khalaf |e verfasserin |4 aut | |
| 700 | 1 | |a Alrabiah, Fahad |e verfasserin |4 aut | |
| 700 | 1 | |a Alshamrani, Majid |e verfasserin |4 aut | |
| 700 | 1 | |a Aldibasi, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Alaskar, Ahmed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases |d 1995 |g 28(2022), 4 vom: 01. Apr., Seite 602-608 |w (DE-627)NLM094580014 |x 1469-0691 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:4 |g day:01 |g month:04 |g pages:602-608 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cmi.2021.12.026 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 4 |b 01 |c 04 |h 602-608 | ||